First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects.

Detalles Bibliográficos
Publicado en:Stroke (00392499) Vol. 55; no. 12; pp. 2795 - 2804
Autores principales: Manna, Lisa M., Hernandez, Juan, Hunt, Dawn E., Lakner, Géza, Matson, Mark A., Poe, Russell B., Korinek, William S., Lancey, Robert A., Liston, Theodore E.
Formato: Journal Article
Publicado: Lippincott Williams & Wilkins Dec2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181039982&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 181039982
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00392499
        1FT
      jtl: Stroke (00392499)
      issn: 00392499
      maglogo: N
    pubinfo:
      dt: Dec2024
      vid: 55
      iid: 12
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        181039982
        10.1161/STROKEAHA.124.047207
        181039982
      ppf: 2795
      ppct: 9
      formats:
      tig:
        atl: First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects.
      aug:
        au:
          Manna, Lisa M.
          Hernandez, Juan
          Hunt, Dawn E.
          Lakner, Géza
          Matson, Mark A.
          Poe, Russell B.
          Korinek, William S.
          Lancey, Robert A.
          Liston, Theodore E.
        affil: Astrocyte Pharmaceuticals, Inc, Groton, CT (L.M.M., J.H., D.E.H., M.A.M., T.E.L., R.B.P., W.S.K., R.A.L.).
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N